Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.

Certain members of MotivHealth's HSA-based insurance plans will have access to DecisionRx's medication therapy optimization program.

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.